Navigation Links
Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery
Date:8/22/2011

SANTA ANA, Calif., Aug. 22, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it has expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) with the European CE Mark of Healon EndoCoat OVD.

The  clear, viscous, low molecular weight dispersive OVD is intended for use as a surgical aid in cataract extraction, intraocular lens (IOL) implantation, corneal transplantation, and glaucoma filtration surgery.

Healon EndoCoat OVD's formula protects and coats the eye when injected during surgery, and is ideal for intraocular lens (IOL) lubrication and insertion. Additionally, Healon EndoCoat OVD can be used in combination with any other Healon products such as Healon OVD, Healon GV OVD or Healon5 OVD.

Dispersives such as Healon EndoCoat OVD are expected to account for 38 percent of the total OVD market in 2011, according to independent ophthalmic research firm Market Scope.

The Healon EndoCoat OVD delivery system includes a number of features for increased patient safety and ease of handling for the physician, including a smaller, 25-gauge cannula with guard and improved ergonomics of the device for a smooth and consistent delivery.

"Healon EndoCoat [OVD] plays an essential role in my cataract surgeries for overall endothelial cell preservation and patient safety," said Donald Nixon, M.D., surgical director, TriMed Eye Center, Barrie, Ontario, Canada. "Additionally, the mechanical properties of Healon EndoCoat [OVD] provide me with the stability I need throughout the entire cataract procedure for even the most challenging cases."

Healon EndoCoat OVD is available in Europe, Canada and New Zealand and is currently under review by the U.S. Food and Drug Administration. Shipments to other geographies will follow once the company receives necessary regulatory approvals.  Customers who already receive regular shipment
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
(Date:4/17/2014)... one in five infants in the United States annually ... several months after birth. Research into probiotic use for ... April 1, 2014 issue of the British Medical ... "Probiotics and Infant Colic," concluding that the use of ... did not reduce crying or fussing in infants ...
(Date:4/17/2014)... ward off depression among retirees, particularly among those who ... The Journals of Gerontology, Series B: Psychological Sciences ... Internet Use and Depression Among Retired Older Adults in ... report that Internet use reduced the probability of a ... , Late-life depression affects between 5 and 10 ...
(Date:4/17/2014)... general blood flow and alleviates muscle soreness after ... the University of Illinois at Chicago. , The ... the Archives of Physical Medicine and Rehabilitation ... in people who had not exercised, suggesting that ... level of physical activity. , Improved circulation and ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... HILL In 2006, University of North Carolina at Chapel ... levels of LDL cholesterol are more likely to have Parkinson,s ... study could not answer the question of whether low LDL ... were diagnosed with Parkinsons, or if they developed low LDL ...
... Program Will Put Home Medical Equipment Providers out of,Business ... Million Seniors and,Disabled People in Kansas City Area, ... program for durable medical equipment (DME) scheduled to be,implemented ... 1,2008, will put many DME providers out of business ...
... April 4, 2008 Most people assume,that cancer is ... Cancer Society, healthy behaviors could prevent approximately half,of cancer ... all based on the,latest research, which people can make ... at its earliest, most curable stages., -- Don,t ...
... they might want to avoid theft of Social Security checks ... finds that senior citizens in Baltimore seem to avoid visiting ... because they want to stay home and make sure no ... help doctors get a better handle on fluctuations in when ...
... April 4, 2008 -- A promising vaccine being tested ... do -- clear beta-amyloid plaques from the brain -- ... learning and memory abilities, according to a University of ... the predominant pathology of Alzheimer,s disease -- beta-amyloid plaques ...
... ward off gastroenteritis, which causes vomiting and diarrhea in children ... and Drug Administration has approved a second oral vaccine for ... diarrhea in infants and children. , The Rotarix vaccine is ... from 6 to 24 weeks of age. , ...
Cached Medicine News:Health News:Pieces coming together in Parkinson's, cholesterol puzzle 2Health News:Medicare Bidding Program in Kansas City is Plagued by Problems, Says American Association for Homecare 2Health News:Medicare Bidding Program in Kansas City is Plagued by Problems, Says American Association for Homecare 3Health News:Ten Things You Can Do to Reduce Your Cancer Risk 2Health News:Ten Things You Can Do to Reduce Your Cancer Risk 3Health News:Ten Things You Can Do to Reduce Your Cancer Risk 4Health News:Ten Things You Can Do to Reduce Your Cancer Risk 5Health News:Seniors Avoid ER at Start of Month 2Health News:Seniors Avoid ER at Start of Month 3Health News:Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment 2Health News:FDA OKs New Rotavirus Vaccine 2Health News:FDA OKs New Rotavirus Vaccine 3
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
20 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
Sharp tip with cutting edge bent to 50 degrees fits 19 gauge or 20 gauge instrument port, 20 gauge instrument port, 20 gauge x 25 mm tapering to 25 gauge x 4.76 mm. 10 per box....
Angled, 20 gauge x 25 mm cannula with 30 gauge x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub, angled 45 degrees 2.5 mm from tip. 10 per box....
Medicine Products: